Marc Serra

Nanusens is pioneering sensors built inside CMOS. Nanusens patent-pending technology shrinks MEMS sensors and builds nano-scale sensors (NEMS – Nano Electro Mechanical Systems) along with the control electronics using standard CMOS processes. This creates single chip solutions that are up to ten times smaller than the equivalent multi-package MEMS. The freed-up space can be used for larger batteries for longer operational life battery or additional features. Many different sensors can be built into the same tiny chip to enhance the user experience and differentiate products without taking up more space. Its expertise and pending patents place it as the uncontested leader in this technology that will revolutionise the next generation of sensors. Nanusens also uses its innovative technology to create DTCs (Digital Tuneable Capacitors) or RF switches for 5G smartphones. Again, by shrinking these MEMS into the CMOS layers along with the control electronics on the same die, Nanusens saves space. Founded in 2014 by Dr. Josep Montanyà, Dr. Daniel Fernández and Dr. Marc Llamas, Nanusens is headquartered in London, England with Research and Development offices in Barcelona, Spain and Shenzen, China. It leverages the research and expertise developed by the founders’ previous company, Baolab Microsystems. Nanusens is VC funded by Inveready (www.inveready.com/venture-capital/), Caixa Capital Risc (www.caixacapitalrisc.es/en/) and Dieco Capital (www.dieco-capital.com), and crowdfunding via Crowdcube.

Ability Pharmaceuticals is a clinical-stage biopharmaceutical company committed to develop first-in-class therapies that address unmet medical needs in the oncology space. AbilityPharmas is currently conducting, with ABTL0812, the most advanced asset, an international multi-center, double-blind, placebo-controlled phase 2b clinical trial in patients with metastatic pancreatic cancer to investigate ABTL0812 as first-lin therapy in combination with FOLFIRINOX chemotherapy. The study includes reference centers in Spain, France, United States and Israel. ABTL0812 has finished with very positive results a phase 2a clinical trial as first-line therapy in endometrial cancer and in squamous NSCLC in combination with paclitaxel and carboplatin. The study included leading institutions in Spain and France (Vall d’Hebron Institut d’Oncologia – VHIO, Institut Gustave Roussy, Centre Léon Bérard). ABTL0812 is the first cancer drug killing tumor cells through potent cytotoxic autophagy via inhibition of the Akt/mTOR axis, and the induction of robust endoplasmic reticular stress (ER Stress). Its unique mechanism of action was partially published at Clinical Cancer Research in December 2015 and fully characterized at Autophagy journal in May 2020. The compound has also immunomodulatory effects, turning "cold" immunogenic tumors into "hot" immunogenic. The compound is active as standalone treatment, it has synergy with chemotherapy, and it has synergy with anti PD1 therapies. The product has potential in several cancer types as first-line and maintenance therapy including lung, endometrial, pancreatic, breast, head and neck cancer, glioblastoma, cholangiocarcinoma and the pediatric cancer neuroblastoma. ABTL0812 has been granted Orphan Drug Designation for pancreatic cancer, neuroblastoma, and biliary tract cancer, by the US FDA and the European EMA. Development and marketing rights for Greater China granted to SciClone Pharmaceuticals, Inc.

CogniCor is the leading Generative AI Advisor Copilot platform that fundamentally transforms the financial services sector to reach exponentially greater levels of growth, efficiency and service outcomes.

Intercros is a company specialised in the production and distribution of artisanal frozen pastries and other specialties within the EU. Its value proposition is to offer high quality artisanal products at unbeatable prices, combining the most modern techniques in ultrafreezing with the traditional production processes. Intercros has a strict quality management policy and has been the first company of the sector in Morocco to obtain quality certifications, and already have the IFS certificate. The company has been backed by private and public investment adding up to a total of over a 1M€ since it was founded.

Lánzame es un Pledge Fund de iniciativa privada, que nace con la finalidad de facilitar la conexión entre emprendedores e inversores. Presentamos los proyectos a nuestra red de inversores que, a través del modelo de Pledge Fund de Lánzame, podrán adquirir participaciones en el proyecto mediante la aportación de capital. A través de los encuentros que organizamos, los Lánzame Days, entre el emprendedor y los potenciales inversores, estos pueden resolver las dudas sobre el proyecto directamente de la mano del emprendedor, además de poder conocer al equipo de emprendedores. Lánzame tiene como valor diferencial ser el aliado de confianza tanto para el emprendedor, como para los inversores -mediante la criba y selección de proyectos con mayor potencial- realizando un acompañamiento a ambas partes desde el inicio y durante todo el proceso. A través de Lánzame facilitamos que aquellos inversores que desean invertir en Startups, a través del modelo de co-inversión, puedan hacerlo. En Lánzame hemos conseguido democratizar las inversiones. Startups Participadas: - Kantox - Novicap - Verse - Iristrace - Consentio - Nemuru - Skitude - Keyless - Vottun - Reloadly - Portfolio - Aplanet - Overexport - Dost - Hellotickets - Food For Joe - Kintai - Habitación.com - Floorfy - BrandTrack

Nanusens is pioneering sensors built inside CMOS. Nanusens patent-pending technology shrinks MEMS sensors and builds nano-scale sensors (NEMS – Nano Electro Mechanical Systems) along with the control electronics using standard CMOS processes. This creates single chip solutions that are up to ten times smaller than the equivalent multi-package MEMS. The freed-up space can be used for larger batteries for longer operational life battery or additional features. Many different sensors can be built into the same tiny chip to enhance the user experience and differentiate products without taking up more space. Its expertise and pending patents place it as the uncontested leader in this technology that will revolutionise the next generation of sensors. Nanusens also uses its innovative technology to create DTCs (Digital Tuneable Capacitors) or RF switches for 5G smartphones. Again, by shrinking these MEMS into the CMOS layers along with the control electronics on the same die, Nanusens saves space. Founded in 2014 by Dr. Josep Montanyà, Dr. Daniel Fernández and Dr. Marc Llamas, Nanusens is headquartered in London, England with Research and Development offices in Barcelona, Spain and Shenzen, China. It leverages the research and expertise developed by the founders’ previous company, Baolab Microsystems. Nanusens is VC funded by Inveready (www.inveready.com/venture-capital/), Caixa Capital Risc (www.caixacapitalrisc.es/en/) and Dieco Capital (www.dieco-capital.com), and crowdfunding via Crowdcube.

Ability Pharmaceuticals is a clinical-stage biopharmaceutical company committed to develop first-in-class therapies that address unmet medical needs in the oncology space. AbilityPharmas is currently conducting, with ABTL0812, the most advanced asset, an international multi-center, double-blind, placebo-controlled phase 2b clinical trial in patients with metastatic pancreatic cancer to investigate ABTL0812 as first-lin therapy in combination with FOLFIRINOX chemotherapy. The study includes reference centers in Spain, France, United States and Israel. ABTL0812 has finished with very positive results a phase 2a clinical trial as first-line therapy in endometrial cancer and in squamous NSCLC in combination with paclitaxel and carboplatin. The study included leading institutions in Spain and France (Vall d’Hebron Institut d’Oncologia – VHIO, Institut Gustave Roussy, Centre Léon Bérard). ABTL0812 is the first cancer drug killing tumor cells through potent cytotoxic autophagy via inhibition of the Akt/mTOR axis, and the induction of robust endoplasmic reticular stress (ER Stress). Its unique mechanism of action was partially published at Clinical Cancer Research in December 2015 and fully characterized at Autophagy journal in May 2020. The compound has also immunomodulatory effects, turning "cold" immunogenic tumors into "hot" immunogenic. The compound is active as standalone treatment, it has synergy with chemotherapy, and it has synergy with anti PD1 therapies. The product has potential in several cancer types as first-line and maintenance therapy including lung, endometrial, pancreatic, breast, head and neck cancer, glioblastoma, cholangiocarcinoma and the pediatric cancer neuroblastoma. ABTL0812 has been granted Orphan Drug Designation for pancreatic cancer, neuroblastoma, and biliary tract cancer, by the US FDA and the European EMA. Development and marketing rights for Greater China granted to SciClone Pharmaceuticals, Inc.

Ofrecemos una serie de workshops de formación presencial one-to-one y privadas para que puedas ponerte al día y sacar el máximo partido de LinkedIn a nivel profesional. Son sesiones de formación personalizada en social selling para que puedas vender más y mejor. La venta ha cambiado. Estás preparado? Las startups desarrollan productos y/o servicios. Y también tienen que venderlos. Mostramos cómo hacerlo. Acompañamos a las Pymes con formación y consultoria en social selling y business development. También ofrecemos talleres y cursos in-situ para empresas y altos directivos. Formación personalizada en LinkedIn para potenciar la venta. ​ Consultar la web de BGlobal.cat para ver y contratar cursos y talleres que ofrecemos. Ofrecemos una serie de workshops o talleres de formación presencial one-to-one sobre el uso de LinkedIn como la red social profesional de referencia para el social selling. Estas sesiones privadas face-to-face pueden ser introductorias o avanzadas y el contenido se adapta a cada cliente. Se imparten en nuestras oficinas o en las del cliente. Somos usuarios expertos de LinkedIn. Desde el 2004. Sabemos como utilizar LinkedIn para vender servicios de alto valor añadido a grandes empresas. Lo hemos hecho con mucho éxito y grandes resultados. Queremos compartir contigo nuestra experiencia y ayudarte a desarrollar tu estrategia de social selling evitando cometer los típicos errores. ​ Ahora puedes beneficiarte de nuestra experiencia. Consultoria y coaching en social selling y uso avanzado de LinkedIn.

We have helped educate & inspire over 410K entrepreneurs around the world. We have done over 5,2K events in over 1,475 cities to date. We have thousands of passionate organizers and volunteers that are the driving force in Techstars Startup Weekend’s success. We have helped educate & inspire over 410K entrepreneurs around the world. We have done over 5,2K events in over 1,475 cities to date. We have thousands of passionate organizers and volunteers that are the driving force in Techstars Startup Weekend’s success.